Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial
- Authors
- Kang, Woong Chol; Ahn, Taehoon; Lee, Kyounghoon; Han, Seung Hwan; Shin, Eak Kyun; Jeong, Myung Ho; Yoon, Jung Han; Park, Jong-Seon; Bae, Jang Ho; Hur, Seung Ho; Rha, Seung Woon; Oh, Seok Kyu; Kim, Doo Il; Jang, Yangsoo; Choi, Jae Woong; Kim, Byung Ok
- Issue Date
- 12월-2011
- Publisher
- EUROPA EDITION
- Keywords
- STEMI; Primary PCI; zotarolimus-eluting stents; sirolimus-eluting stents; paclitaxel-eluting stents
- Citation
- EUROINTERVENTION, v.7, no.8, pp.936 - 943
- Indexed
- SCIE
SCOPUS
- Journal Title
- EUROINTERVENTION
- Volume
- 7
- Number
- 8
- Start Page
- 936
- End Page
- 943
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/111077
- DOI
- 10.4244/EIJV7I8A148
- ISSN
- 1774-024X
- Abstract
- Aims: The aim of this study was to compare the efficacy and safety of zotarolimus-eluting stents (ZES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with ST-segment elevation myocardial infarction (STEM I) undergoing primary percutaneous coronary intervention (PCI). Methods and results: This study was a prospective, single-blind, multicentre, randomised trial. The primary endpoint was major adverse cardiac events (MACE) at 12 months post-procedure, defined as cardiac death, recurrent myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (TLR). An angiographic substudy was performed at nine months among 348 patients. From October 2006 to April 2008, 611 patients with STEMI undergoing primary PCI were randomly assigned to treatment with ZES (n=205), SES (n=204), or PES (n=202). The cumulative incidence of MACE was 5.9% in the ZES group, 3.4% in the SES group and 5.7% in the PES group at 12-month follow-up (p=0.457). There was a trend towards a lower rate of ischaemia-driven TLR at 12- (p=0.092) and 18-month (p=0.080) follow-up in the SES group compared to the ZES and PES groups. No difference was observed in rates of cardiac death, recurrent MI and combined death and/or recurrent MI among three groups at 12- and 18-month follow-up. The rate of stent thrombosis was similar among the three groups (2.0% in each group, p=1.000). Conclusions: As compared with SES and PES, the use of ZES in patients with STEMI undergoing primary PCI, showed similar rates of MACE, cardiac death and recurrent MI at 12 and 18 months. There was a trend towards a higher rate of TLR with ZES or PES compared to SES.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.